These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 27794114)

  • 1. Acute cholecystitis during treatment with alemtuzumab in 3 patients with RRMS.
    Pfeuffer S; Beuker C; Ruck T; Lenze F; Wiendl H; Melzer N; Meuth SG
    Neurology; 2016 Nov; 87(22):2380-2381. PubMed ID: 27794114
    [No Abstract]   [Full Text] [Related]  

  • 2. Acute severe hepatitis with alemtuzumab and rechallenge after a year.
    Beattie W; Yan B; Sood S
    J Clin Neurosci; 2019 Feb; 60():158-160. PubMed ID: 30348589
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Acute acalculous cholecystitis: A new safety risk for patients with MS treated with alemtuzumab.
    Croteau D; Flowers C; Kulick CG; Brinker A; Kortepeter CM
    Neurology; 2018 May; 90(18):e1548-e1552. PubMed ID: 29602912
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Acute respiratory distress syndrome following alemtuzumab therapy for relapsing multiple sclerosis.
    Yann K; Jackson F; Sharaf N; Mihalova T; Talbot P; Rog D; Pace A
    Mult Scler Relat Disord; 2017 May; 14():1-3. PubMed ID: 28619423
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Serum sickness (Like Reaction) in a patient treated with alemtuzumab for multiple sclerosis: A case report.
    Lapucci C; Gualandi F; Mikulska M; Palmeri S; Mancardi G; Uccelli A; Laroni A
    Mult Scler Relat Disord; 2018 Nov; 26():52-54. PubMed ID: 30223229
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Early neutropenia with thrombocytopenia following alemtuzumab treatment for multiple sclerosis: case report and review of literature.
    Maniscalco GT; Cerillo I; Servillo G; Napolitano M; Guarcello G; Abate V; Improta G; Florio C
    Clin Neurol Neurosurg; 2018 Dec; 175():134-136. PubMed ID: 30419425
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hemophagocytic syndrome following alemtuzumab treatment for multiple sclerosis: A case report.
    Romero A; Midaglia L; Salcedo MT; Viladomiu L; Guillén E; Bajaña I; Escolà-Vergé L; Tintoré M; Montalban X; Len O
    Mult Scler Relat Disord; 2020 May; 40():101973. PubMed ID: 32028116
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Auto-immune hepatitis in a patient with multiple sclerosis treated with alemtuzumab.
    El Sankari S; Dahlqvist G; Monino L; van Pesch V
    Acta Neurol Belg; 2018 Jun; 118(2):331-333. PubMed ID: 29713905
    [No Abstract]   [Full Text] [Related]  

  • 9. Pneumonitis secondary to alemtuzumab in a patient with multiple sclerosis - A non-infectious cause of breathlessness.
    Whiteside D; Barth S; Datta A; Trip SA
    Mult Scler Relat Disord; 2018 May; 22():139-140. PubMed ID: 29684788
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Acute leukocytosis during alemtuzumab treatment in patients with active relapsing-remitting multiple sclerosis.
    Iovino A; Aruta F; Carotenuto A; Manganelli F; Iodice R
    Mult Scler Relat Disord; 2019 Feb; 28():98-100. PubMed ID: 30580038
    [TBL] [Abstract][Full Text] [Related]  

  • 11. ANCA-associated life-threatening systemic vasculitis after alemtuzumab treatment for multiple sclerosis.
    Horisberger A; Pantazou V; Cuendet G; Ribi C; Dunet V; Théaudin M
    Mult Scler; 2020 Oct; 26(12):1599-1602. PubMed ID: 32081100
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Acute coronary syndrome associated with alemtuzumab infusion in multiple sclerosis.
    Ferraro D; Camera V; Vitetta F; Zennaro M; Ciolli L; Nichelli PF; Sola P
    Neurology; 2018 May; 90(18):852-854. PubMed ID: 29602915
    [No Abstract]   [Full Text] [Related]  

  • 13. Acute myocardial infarction associated with initial alemtuzumab infusion cycle in relapsing-remitting multiple sclerosis.
    Romba MC; Newsome SD; McArthur JC
    Mult Scler Relat Disord; 2019 Sep; 34():100-102. PubMed ID: 31252364
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Life-threatening autoimmune warm hemolytic anemia following treatment for multiple sclerosis with alemtuzumab.
    Meunier B; Rico A; Seguier J; Boutiere C; Ebbo M; Harle JR; Schleinitz N; Pelletier J
    Mult Scler; 2018 May; 24(6):811-813. PubMed ID: 29359614
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pulmonary embolism during the third cycle of alemtuzumab in a patient with relapsing multiple sclerosis.
    Habek M; Ruška B; Pavičić T; Alduk AM; Gabelić T; Adamec I
    Mult Scler Relat Disord; 2019 Oct; 35():5-6. PubMed ID: 31276912
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Disseminated necrotizing leukoencephalopathy eight months after alemtuzumab treatment for multiple sclerosis.
    Metz I; Rieckmann P; Kallmann BA; Brück W
    Acta Neuropathol Commun; 2016 Aug; 4(1):81. PubMed ID: 27503238
    [No Abstract]   [Full Text] [Related]  

  • 17. Neutropenia in Patients With Multiple Sclerosis Treated With Alemtuzumab.
    Gaitán MI; Ysrraelit MC; Correale J
    JAMA Neurol; 2017 Sep; 74(9):1143-1144. PubMed ID: 28715536
    [No Abstract]   [Full Text] [Related]  

  • 18. A case of anaphylaxis to alemtuzumab.
    Nye CJS; Wagner A; Kousin-Ezewu O; Jones JL; Coles AJ
    J Neurol; 2019 Mar; 266(3):780-781. PubMed ID: 30715557
    [No Abstract]   [Full Text] [Related]  

  • 19. Severe bradycardia: An unreported adverse infusion-associated reaction (IAR) with alemtuzumab.
    Nerrant E; Thouvenot E; Castelnovo G
    Rev Neurol (Paris); 2017 Mar; 173(3):175-176. PubMed ID: 28320519
    [No Abstract]   [Full Text] [Related]  

  • 20. Simultaneous early-onset immune thrombocytopenia and autoimmune thyroid disease following alemtuzumab treatment in relapsing-remitting multiple sclerosis.
    Obermann M; Ruck T; Pfeuffer S; Baum J; Wiendl H; Meuth SG
    Mult Scler; 2016 Aug; 22(9):1235-41. PubMed ID: 26980848
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.